Justia U.S. Federal Circuit Court of Appeals Opinion Summaries

US Synthetic Corp. (USS) filed a complaint with the United States International Trade Commission (Commission) alleging that several intervenors violated 19 U.S.C. § 1337 by importing and selling products that infringe five of USS’s patents. The focus of this appeal is U.S. Patent No. 10,508,502 (’502 patent), which claims a polycrystalline diamond compact (PDC) with specific structural and magnetic properties.The Commission instituted an investigation, and the administrative law judge (ALJ) determined that the asserted claims of the ’502 patent were infringed and not invalid under 35 U.S.C. §§ 102, 103, or 112. However, the ALJ found the claims patent ineligible under 35 U.S.C. § 101, as they were directed to an abstract idea. The Commission reviewed and affirmed the ALJ’s determination, concluding that the claims were directed to the abstract idea of achieving desired magnetic properties, which were seen as side effects of the manufacturing process.The United States Court of Appeals for the Federal Circuit reviewed the case. The court concluded that the asserted claims of the ’502 patent are not directed to an abstract idea but to a specific, non-abstract composition of matter defined by its constituent elements, dimensional information, and quantified material properties. The court found that the magnetic properties are integrally related to the structure of the PDC and are not merely side effects. Therefore, the claims are not directed to an abstract idea under Alice step one, and the court did not reach Alice step two.The court also addressed the alternative argument that the claims were not enabled. The court found no error in the Commission’s conclusion that the claims were enabled, as the respondents failed to prove a lack of enablement by clear and convincing evidence. The court reversed the Commission’s conclusion on patent ineligibility, affirmed the enablement conclusion, and remanded the case. View "US SYNTHETIC CORP. v. ITC " on Justia Law

Pirelli Tyre Co., Ltd. (Pirelli China), a foreign producer and exporter of certain tires, sought to establish independence from the Chinese government to obtain a separate antidumping duty rate. The United States Department of Commerce conducted an administrative review of merchandise covered by a 2015 antidumping-duty order for tires from China, covering entries between August 1, 2017, and July 31, 2018. Commerce applied a rebuttable presumption that all exporters within China are subject to government control, assigning a PRC-wide antidumping-duty rate unless the exporter demonstrates sufficient independence.The United States Court of International Trade (Trade Court) upheld Commerce’s determination that Pirelli China had not demonstrated its independence from government control. Commerce found that Pirelli China did not show autonomy from the Chinese government in selecting its management, a key criterion for obtaining a separate rate. Pirelli China’s arguments based on Italian law were rejected because the relevant provisions were not included in the record.The United States Court of Appeals for the Federal Circuit reviewed the case and affirmed the Trade Court’s decision. The court held that Commerce’s interpretation of the rebuttable presumption and its requirement for Pirelli China to demonstrate autonomy from government control were reasonable. The court also found that Commerce’s determination was supported by substantial evidence, including the indirect ownership and control by state-owned enterprises and the shared management between Pirelli entities and Chinese government-controlled entities. The court concluded that Commerce acted within its discretion in rejecting Pirelli China’s unsupported interpretations of Italian law and upheld the assignment of the PRC-wide antidumping-duty rate to Pirelli China. View "PIRELLI TYRE CO., LTD. v. US " on Justia Law

In 1957, Congress enacted the Price-Anderson Act (PAA) to amend the Atomic Energy Act of 1954, providing indemnity for contractors and others involved in nuclear activities. The PAA mandated that the government indemnify contractors and other "persons indemnified" for public liability arising from nuclear incidents. In 1962, the Atomic Energy Commission (AEC) entered into an indemnity agreement with Mallinckrodt Chemical Works, which processed uranium for the government. Cotter Corporation later purchased radioactive materials from Mallinckrodt and was sued in 2012 by plaintiffs alleging harm from these materials.The United States Court of Federal Claims dismissed Cotter's claim for indemnification under the PAA and the indemnity agreement, ruling that Cotter was not entitled to indemnification because its activities did not arise out of or in connection with the contractual activities of Mallinckrodt. The court also dismissed Cotter's contract claim, concluding that Cotter lacked standing as a third-party beneficiary and failed to state a claim for breach of contract.The United States Court of Appeals for the Federal Circuit reviewed the case and reversed the Claims Court's decision. The Federal Circuit held that Cotter's liability for the nuclear incident plausibly arose out of or in connection with the contractual activities of Mallinckrodt, as the materials causing the incident were produced under the contract. The court also found that Cotter sufficiently alleged it was an intended third-party beneficiary of the indemnity agreement and that the government breached the contract by not indemnifying Cotter. The case was remanded for further proceedings. View "COTTER CORP., N.S.L. v. US " on Justia Law

Kroy IP Holdings, LLC sued Groupon, Inc. in the United States District Court for the District of Delaware, alleging patent infringement of U.S. Patent No. 6,061,660, which relates to providing incentive programs over a computer network. Groupon moved to dismiss the complaint, arguing that Kroy was collaterally estopped from alleging infringement based on two prior inter partes review (IPR) decisions by the Patent Trial and Appeal Board (PTAB) that found other claims of the same patent unpatentable.The district court granted Groupon’s motion to dismiss, determining that the PTAB’s final judgments on the unpatentability of certain claims had preclusive effect on the district court action. The court concluded that collateral estoppel could apply to patent claims not previously adjudicated if the differences between the unadjudicated and adjudicated claims did not materially alter the question of invalidity. The district court found that the newly asserted claims were immaterially different from the previously adjudicated claims and thus dismissed Kroy’s complaint with prejudice.The United States Court of Appeals for the Federal Circuit reviewed the case and reversed the district court’s decision. The Federal Circuit held that collateral estoppel does not apply when the second action involves a different legal standard, such as a different burden of proof. The court noted that in IPR proceedings, the burden of proof is a preponderance of the evidence, whereas in district court, the burden is clear and convincing evidence. Therefore, the PTAB’s findings under a lower burden of proof could not preclude Kroy from asserting the newly asserted claims in district court. The Federal Circuit reversed the district court’s dismissal and remanded the case for further proceedings. View "KROY IP HOLDINGS, LLC v. GROUPON, INC. " on Justia Law

Wuhan Healthgen Biotechnology Corp. (Healthgen) appealed a final determination from the International Trade Commission (Commission) which found that Healthgen’s clinical grade albumin products infringed claims of U.S. Patent No. 10,618,951, owned by Ventria Bioscience Inc. (Ventria). The patent pertains to cell culture media containing recombinant human serum albumin produced in a genetically modified plant. Healthgen imports clinical and medium grade recombinant human serum albumin (rHSA) products, and Ventria alleged that these imports violated Section 337 of the Tariff Act of 1930 due to patent infringement.The Administrative Law Judge (ALJ) initially found that Healthgen’s clinical and medium grade rHSA products infringed the patent and that Ventria satisfied the domestic industry requirement based on six rHSA products. The Commission affirmed the ALJ’s finding of infringement for the clinical grade products but not for the medium grade products. The Commission also affirmed that Ventria satisfied the domestic industry requirement based on one product, Optibumin, without further analysis of the other five products.The United States Court of Appeals for the Federal Circuit reviewed the case. The court held that substantial evidence supported the Commission’s findings. The court affirmed the Commission’s determination that Healthgen’s clinical grade products infringed the patent based on SEC-HPLC data showing less than 2% aggregated albumin. The court also upheld the Commission’s finding that Ventria satisfied the domestic industry requirement, noting that all investments and activities related to Optibumin occurred within the United States and that the investment-to-revenue ratio indicated significant investment despite low revenue.The Federal Circuit affirmed the Commission’s decision, concluding that Healthgen’s clinical grade products infringed the patent and that Ventria met the domestic industry requirement. View "WUHAN HEALTHGEN BIOTECHNOLOGY CORP. v. ITC " on Justia Law

Trudell Medical International Inc. (Trudell) owns U.S. Patent No. 9,808,588, which relates to devices for performing oscillatory positive expiratory pressure (OPEP) therapy. Trudell sued D R Burton Healthcare, LLC (D R Burton) for patent infringement. D R Burton sells OPEP devices, including the vPEP®, vPEP® HC, iPEP®, PocketPEP®, and PocketPEP® Advantage products. Trudell alleged that these products infringed certain claims of the ’588 patent.The United States District Court for the Eastern District of North Carolina allowed D R Burton to present infringement testimony by Dr. John Collins at trial. After a three-day trial, the jury found that the asserted claims of the ’588 patent were valid but not infringed. Trudell filed a renewed motion for judgment as a matter of law (JMOL) on infringement or, alternatively, for a new trial. The district court denied this motion.The United States Court of Appeals for the Federal Circuit reviewed the case. The court held that the district court abused its discretion by allowing Dr. Collins to testify on noninfringement because his testimony was untimely and did not comply with Federal Rule of Civil Procedure 26. Additionally, the court found Dr. Collins' testimony unreliable under Federal Rule of Evidence 702. The Federal Circuit vacated the jury’s finding of noninfringement and remanded for a new trial, excluding Dr. Collins’ noninfringement testimony. The court also affirmed the district court’s denial of Trudell’s motion for JMOL of infringement, as the jury could have reasonably found noninfringement based on the evidence presented.The Federal Circuit ordered that the case be reassigned to a different district court judge on remand to preserve the appearance of justice and fairness, given the trial judge’s statements indicating a predisposition to quickly resolve the case. View "TRUDELL MEDICAL INTERNATIONAL INC. v. D R BURTON HEALTHCARE, LLC " on Justia Law

A veteran of the United States Air Force, Clinton Siples, was granted service connection for bilateral shoulder subluxation by a Regional Office (RO) of the United States Department of Veterans Affairs (VA). After the decision became final, the United States Court of Appeals for Veterans Claims (Veterans Court) decided Burton v. Shinseki, which interpreted 38 C.F.R. § 4.59 as not limited to cases of arthritis. Mr. Siples then filed a motion alleging clear and unmistakable error (CUE) in the RO’s rating decision, arguing that the newly interpreted § 4.59 would have required the VA to assign him a higher rating for his shoulder disability, which was not based on arthritis.The Veterans Court affirmed the Board of Veterans’ Appeals’ (Board) denial of Mr. Siples’s CUE motion, stating that at the time of his rating decision, § 4.59 was not undebatably understood to apply to cases other than arthritis, and thus there was no error of the type required for CUE. The Veterans Court applied the standard that CUE must be analyzed based on the law as it was understood at the time of the original decision and cannot arise from a subsequent change in the law or interpretation thereof.The United States Court of Appeals for the Federal Circuit reviewed the case and affirmed the Veterans Court’s decision. The Federal Circuit held that CUE must be based on the law at the time of the decision, and at the time of the RO’s decision in Mr. Siples’s case, § 4.59 was not undebatably understood as applying to cases other than arthritis. The court concluded that the regulation’s plain language did not clearly apply to non-arthritis claims, and the understanding of § 4.59 in July 2004 did not undebatably require the RO to assign a higher rating to Mr. Siples’s non-arthritic shoulder disability. View "SIPLES v. COLLINS " on Justia Law

HD Silicon Solutions LLC (HDSS) appealed a decision by the United States Patent and Trademark Office Patent Trial and Appeal Board (the Board) which held claims 1–7 and 9–17 of U.S. Patent 6,774,033 (the '033 patent) unpatentable as obvious. The '033 patent pertains to a local interconnect layer in an integrated circuit, specifically involving a method of forming this layer using titanium nitride and tungsten films.Microchip Technology Inc. (Microchip) petitioned for inter partes review (IPR), arguing that the claims were obvious over U.S. Patent 5,847,463 (Trivedi). The Board construed the term "comprising tungsten" to include both elemental tungsten and tungsten compounds, and found that the claims were unpatentable based on Trivedi alone or in combination with other references. HDSS appealed this decision, challenging the Board's claim construction and its findings on the motivation to combine references.The United States Court of Appeals for the Federal Circuit reviewed the case. The court agreed with HDSS that the Board's construction of "comprising tungsten" was incorrect, determining that the term should be limited to elemental tungsten. However, the court found that this error was harmless because Trivedi disclosed both elemental tungsten and tungsten-silicide layers, either of which would render the claims obvious. The court also upheld the Board's findings on the motivation to combine references, rejecting HDSS's arguments that the Board misinterpreted Trivedi and failed to explain the motivation to combine references to meet specific claim limitations.Ultimately, the Federal Circuit affirmed the Board's decision, holding that the claims of the '033 patent were unpatentable as obvious. View "HD SILICON SOLUTIONS LLC v. MICROCHIP TECHNOLOGY INC. " on Justia Law

The case involves 27-35 Jackson Avenue LLC ("Jackson"), the owner of a New York City office building, which leased two floors to the United States government for the United States Citizenship and Immigration Services (USCIS) Field Office. The lease, starting in May 2009, included a clause allowing termination if the premises were rendered untenantable by fire or other casualty, as determined by the government. In January 2015, a burst sprinkler head caused extensive water damage, leading the government to vacate the premises and eventually terminate the lease, citing untenantability.The United States Court of Federal Claims granted summary judgment in favor of the government, finding that the government did not breach the lease agreement. The court held that the government’s determination of untenantability was within its discretion and was not made in bad faith. Jackson's claim that the government acted unreasonably and in bad faith was rejected, as the court found no evidence to support these allegations.The United States Court of Appeals for the Federal Circuit reviewed the case and affirmed the lower court's decision. The appellate court held that the government’s determination of untenantability was not arbitrary, capricious, or unreasonable. The court emphasized that the lease explicitly allowed the government to make this determination. Additionally, the court found that Jackson failed to provide clear and convincing evidence of bad faith or a breach of the implied covenant of good faith and fair dealing. The court concluded that the government acted within its contractual rights and upheld the summary judgment in favor of the government. View "27-35 JACKSON AVE LLC v. US " on Justia Law

Gesture Technology Partners, LLC owns U.S. Patent No. 8,878,949, which is directed to image capture technology using a portable device with an electro-optical sensor and a digital camera. Apple Inc. filed an inter partes review (IPR) petition challenging the patent's claims as obvious over prior art references Numazaki and Nonaka. The Patent Trial and Appeal Board (the "Board") found claims 1-3, 5-10, and 12-17 unpatentable but upheld claims 4, 11, and 18. Gesture cross-appealed the unpatentability findings, and Apple appealed the findings regarding claims 4, 11, and 18.The Board concluded that claims 1-3 and 5-7 were obvious based on the combination of Numazaki and Nonaka, which disclosed a device that captures images in response to detected gestures. However, the Board found that claim 4, which required the electro-optical sensor to be "fixed" in relation to the digital camera, was not obvious because Numazaki did not disclose this limitation.The United States Court of Appeals for the Federal Circuit reviewed the case. The court affirmed the Board's determination that claims 1-3 and 5-7 were unpatentable. The court found that the Board had substantial evidence to support its conclusion that a person of ordinary skill in the art would combine the teachings of Numazaki and Nonaka to render these claims obvious.However, the court reversed the Board's determination regarding claim 4. The court found that the Board had improperly ignored Apple’s expert testimony, which demonstrated that fixing the electro-optical sensor and digital camera in relation to each other was desirable and obvious to a person of ordinary skill in the art. The court concluded that the record showed that the fixed relationship was necessary to maintain overlapping fields of view, which was essential for the device's functionality.The Federal Circuit affirmed the Board's findings for claims 1-3 and 5-7 and reversed the finding for claim 4, holding it unpatentable. View "APPLE INC. v. GESTURE TECHNOLOGY PARTNERS, LLC " on Justia Law